Drug Trial Radar · NCT04727424
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
7,819
Planned (sponsor's estimate)
Start
Jan 19, 2021
Primary completion
Jun 1, 2024
Study completion Jul 1, 2024
Sponsor
- Lead sponsor
- CardresearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cytel Inc.; McMaster University; Fastgrants; Eiger BioPharmaceuticals; RainWater Foundation
- First posted
- Jan 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild symptoms. Experimental studies have demonstrated a potential anti-inflammatory role of Fluvoxamine, Fluoxetine, Budesonide and Spirulin Platensis in SARS-CoV-2 infections and observational studies have suggested a reduced complications in patients with COVID-19 disease.
Conditions
- Covid19
- SARS-Associated Coronavirus
Interventions
Spirulin PlatensisDietary supplement
Two tablets every 12 hours since randomization through day 09 following randomization
Budesonide PowderDrug
One Fluvoxamine tablet every 12 hours since randomization through day 09. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 09.
Fluoxetine 20 MGDrug
Two Fluoxetine tablets every day starting just after randomization through day 07. PLUS 01 Budesonide powder (inhalation) every 12 hours since randomization through day 07.
PlaceboDrug
Placebo oral tablets (10-day schedule): Matching tablets started after randomization using the dosing regimen of 01 tablet every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule) PLUS Placebo Inhalation Therapy: One dosing (inhalation puff) right after randomization (Day 0) followed by one puff BID for the following 09 days OR Paracetamol (07-day schedule - active comparator): Paracetamol 500 mg tablets started after randomization using the dosing regimen of 01 tablet BID starting at Rand. Day (Day 0) until end of Day 06 (total of 07 days schedule - ANTICOV Arm) OR Matching tablets started after randomization using the dosing regimen of 02 tablets every 12 hs starting at Randomization Day (Day 0) until end of Day 09 (total of 10 day schedule)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in emergency care visits due to the worsening of COVID-19;Time frame: 28 days
- Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing the need for Hospitalization due to COVID-19 progression and related complications, including lower respiratory tract infection (LRTI)Time frame: 28 days
- Rate of fluvoxamine + budesonide, fluoxetine + budesonide, Spirulin platensis in changing SPO2 ≤ 93% after randomizationTime frame: 28 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
CARDRESEARCH - Cardiologia Assistencial e de Pesquisa
Belo Horizonte, Minas Gerais, Brazil · Recruiting
City of Betim
Betim, Minas Gerais, Brazil · Recruiting
City of Brumadinho
Brumadinho, Minas Gerais, Brazil · Not yet recruiting
Hospital e Maternidade Santa Rita
Contagem, Minas Gerais, Brazil · Recruiting
City of Governador Valadares
Governador Valadares, Minas Gerais, Brazil · Recruiting
City of Ibirité
Ibirité, Minas Gerais, Brazil · Recruiting
City of Igarapé
Igarapé, Minas Gerais, Brazil · Recruiting
Centro Universitário FIPMOC
Montes Claros, Minas Gerais, Brazil · Recruiting
City of Nova Lima
Nova Lima, Minas Gerais, Brazil · Recruiting
Universidade Federal de Ouro Preto
Ouro Preto, Minas Gerais, Brazil · Recruiting
City of Santa Luzia
Santa Luzia, Minas Gerais, Brazil · Recruiting
City of Sete Lagoas
Sete Lagoas, Minas Gerais, Brazil · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.